Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation

Clive Kearon

Daniel Victor Ortigoza: Lower Bleeding Rates with Apixaban in Acute VTE Treatment
Jul 25, 2026, 07:03 | Science
Daniel Victor Ortigoza: Lower Bleeding Rates with Apixaban in Acute VTE Treatment
Daniel Victor Ortigoza, Vice Chair of the Argentine Federation of Cardiology’s Cardio-Oncology Committee, shared a…
Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
Mar 29, 2026, 16:15 | Science
Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared a post on LinkedIn…
Yonah S. Tehrani: Providing Clarity for Anticoagulant Selection in Acute Venous Thromboembolism
Mar 26, 2026, 17:25 | Science
Yonah S. Tehrani: Providing Clarity for Anticoagulant Selection in Acute Venous Thromboembolism
Yonah S. Tehrani, Physician at Shaare Zedek Medical Center, Jerusalem, shared a post on LinkedIn about…
Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?
Mar 26, 2026, 16:56 | Science
Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?
Anu Anna Babu, Clinical Pharmacist Intern at Believers Church Medical College Hospital, shared a post…
Mazou Ngou Temgoua: Why Does Apixaban Cause Less Bleeding than Rivaroxaban?
Mar 23, 2026, 15:46 | Science
Mazou Ngou Temgoua: Why Does Apixaban Cause Less Bleeding than Rivaroxaban?
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn about a…
Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
Mar 20, 2026, 17:35 | Science
Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
Bawan Ahmed, Lecturer at University of Greenwich, shared a post on LinkedIn about a recent…
Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Mar 19, 2026, 17:14 | Science
Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent…
Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
Mar 18, 2026, 16:34 | Voices
Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
Richard Buka, Academic Clinical Lecturer at University of Birmingham, shared a post on LinkedIn about…
Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
Mar 17, 2026, 14:55 | Science
Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of…
Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Mar 13, 2026, 16:51 | Science
Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on…
Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Mar 13, 2026, 16:44 | Voices
Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a…
Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority
Mar 11, 2026, 23:05 | Science
Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a…
The Results of Landmark COBRRA Trial in Acute VTE Management - ISTH
Mar 11, 2026, 22:01 | Science
The Results of Landmark COBRRA Trial in Acute VTE Management - ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn about a recent article…
All: 13 Posts: 1 - 100
NewsFeed